-
Je něco špatně v tomto záznamu ?
Costs of multiple sclerosis - extrapolation of Czech data to Polish patients
D. Szmurło, T. Fundament, M. Ziobro, K. Kruntorádová, T. Doležal, C. Głogowski,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2001-10-01 do 2014-08-31
Nursing & Allied Health Database (ProQuest)
od 2001-10-01 do 2014-08-31
Health & Medicine (ProQuest)
od 2001-10-01 do 2014-08-31
- MeSH
- lidé MeSH
- osobní újma zaviněná nemocí * MeSH
- roztroušená skleróza ekonomika MeSH
- zdravotnické zdroje statistika a číselné údaje MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Polsko MeSH
AIMS: To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS: Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapolated to Polish patients and combined with Polish unit costs in 2012. The mean annual costs from societal and payers perspective were calculated for patients according to EDSS. RESULTS: The estimated mean annual cost per patient with MS from a societal perspective ranges from 6970 EUR to 26,791 EUR. Indirect costs (production loss due to early retirement, sick-leave and informal care) cover up to 70% of total costs. CONCLUSIONS: With an estimated 40-60,000 patients with MS in Poland, the disease poses a high economic burden. Indirect costs have a substantial share in these costs. A high-quality prospective study on costs is needed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20014831
- 003
- CZ-PrNML
- 005
- 20200929121042.0
- 007
- ta
- 008
- 200922s2014 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1586/14737167.2014.906305 $2 doi
- 035 __
- $a (PubMed)24702130
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Szmurło, Daria $u HTA Consulting, ul. Starowiślna 17/3, 31-038 Kraków, Poland.
- 245 10
- $a Costs of multiple sclerosis - extrapolation of Czech data to Polish patients / $c D. Szmurło, T. Fundament, M. Ziobro, K. Kruntorádová, T. Doležal, C. Głogowski,
- 520 9_
- $a AIMS: To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS: Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapolated to Polish patients and combined with Polish unit costs in 2012. The mean annual costs from societal and payers perspective were calculated for patients according to EDSS. RESULTS: The estimated mean annual cost per patient with MS from a societal perspective ranges from 6970 EUR to 26,791 EUR. Indirect costs (production loss due to early retirement, sick-leave and informal care) cover up to 70% of total costs. CONCLUSIONS: With an estimated 40-60,000 patients with MS in Poland, the disease poses a high economic burden. Indirect costs have a substantial share in these costs. A high-quality prospective study on costs is needed.
- 650 12
- $a osobní újma zaviněná nemocí $7 D017281
- 650 _2
- $a zdravotnické zdroje $x statistika a číselné údaje $7 D006295
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a roztroušená skleróza $x ekonomika $7 D009103
- 651 _2
- $a Česká republika $7 D018153
- 651 _2
- $a Polsko $7 D011044
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Fundament, Tomasz
- 700 1_
- $a Ziobro, Maciej
- 700 1_
- $a Kruntorádová, Klára
- 700 1_
- $a Doležal, Tomáš
- 700 1_
- $a Głogowski, Cezary
- 773 0_
- $w MED00174435 $t Expert review of pharmacoeconomics & outcomes research $x 1744-8379 $g Roč. 14, č. 3 (2014), s. 451-458
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24702130 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200922 $b ABA008
- 991 __
- $a 20200929121038 $b ABA008
- 999 __
- $a ok $b bmc $g 1567692 $s 1104991
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 14 $c 3 $d 451-458 $e 20140407 $i 1744-8379 $m Expert review of pharmacoeconomics & outcomes research $n Expert rev. pharmacoecon. outcomes res. $x MED00174435
- LZP __
- $a Pubmed-20200922
